SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hellstrom Lindberg E)
 

Search: WFRF:(Hellstrom Lindberg E) > A validated decisio...

  • Hellstrom-Lindberg, E.Karolinska Institutet,Hellström-Lindberg, E., Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden, Department of Medicine, Karolinska Institute, Huddinge University Hospital, 141 86 Stockholm, Sweden (author)

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor : Significant effects on quality of life

  • Article/chapterEnglish2003

Publisher, publication year, extent ...

  • 2003-03-18
  • Wiley,2003
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-46701
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-46701URI
  • https://doi.org/10.1046/j.1365-2141.2003.04153.xDOI
  • https://lup.lub.lu.se/record/316320URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1929798URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-65845URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • We have published previously a prototype of a decision model for anaemic patients with myelodysplastic syndromes (MDS), in which transfusion need and serum erythropoietin (S-Epo) were used to define three groups with different probabilities of erythroid response to treatment with granulocyte colony-stimulating factor (G-CSF) + Epo. S-Epo = 500 U/l and a transfusion need of < 2 units/month predicted a high probability of response to treatment, S-Epo > 500 U/l and =2 units/month for a poor response, whereas the presence of only one negative prognostic marker predicted an intermediate response. A total of 53 patients from a prospective study were included in our evaluation sample. Patients with good or intermediate probability of response were treated with G-CSF + Epo. The overall response rate was 42% with 28.3% achieving a complete and 13.2% a partial response to treatment. The response rates were 61% and 14% in the good and intermediate predictive groups respectively. The model retained a significant predictive value in the evaluation sample (P < 0.001). Median duration of response was 23 months. Scores for global health and quality of life (QOL) were significantly lower in MDS patients than in a reference population, and fatigue and dyspnoea was significantly more prominent. Global QOL improved in patients responding to treatment (P = 0.01). The validated decision model defined a subgroup of patients with a response rate of 61% (95% confidence interval 48-74%) to treatment with G-CSF + Epo. The majority of these patients have shown complete and durable responses.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Gulbrandsen, N.Department of Haematology, Ullevål Hospital, Oslo, Norway (author)
  • Lindberg, G.Karolinska Institutet,Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden (author)
  • Ahlgren, T.Depts. Med./Haematol. the Hospitals, Malmö, Sweden (author)
  • Dahl, I.M.S.Depts. Med./Haematol. the Hospitals, Tromsö, Norway (author)
  • Dybedal, I.Depts. Med./Haematol. the Hospitals, Trondheim, Norway (author)
  • Grimfors, G.Uppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar (author)
  • Hesse-Sundin, E.Karolinska Hospital, Eskilstuna, Sweden (author)
  • Hjorth, M.Karolinska Hospital, Lidköping, Sweden (author)
  • Kanter-Lewensohn, L.Karolinska Institutet,Department of Pathology, Karolinska Hospital, Stockholm, Sweden (author)
  • Linder, O.Karolinska Hospital, Örebro, Sweden (author)
  • Luthman, M.St. Göran Hospital, Stockholm, Sweden (author)
  • Lofvenberg, E.Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Onko (author)
  • Oberg, G.Öberg, G., St. Göran Hospital, Uppsala, Sweden (author)
  • Porwit-MacDonald, A.Karolinska Institutet,Department of Pathology, Karolinska Hospital, Stockholm, Sweden (author)
  • Rådlund, AndersÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US(Swepub:liu)andra74 (author)
  • Samuelsson Johannesson, JannicaKarolinska Institutet,Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Southern Hospital, Stockholm, Sweden(Swepub:lu)med-jsl (author)
  • Tangen, J.M.Department of Haematology, Ullevål Hospital, Oslo, Norway (author)
  • Winquist, I.Southern Hospital, Lund, Sweden (author)
  • Wisloff, F.Department of Haematology, Ullevål Hospital, Oslo, Norway (author)
  • Karolinska InstitutetHellström-Lindberg, E., Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden, Department of Medicine, Karolinska Institute, Huddinge University Hospital, 141 86 Stockholm, Sweden (creator_code:org_t)

Related titles

  • In:British Journal of Haematology: Wiley120, s. 1037-0007-10481365-2141
  • In:Br J Haematol: Wiley120, s. 1037-

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view